- Conditions
- Breast Cancer, Early-stage Breast Cancer, High Risk Breast Carcinoma
- Interventions
- Abemaciclib, Tamoxifen, Anastrozole, Letrozole, Exemestane, LHRH Agonist
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 12
- States / cities
- Stamford, Connecticut • Brewer, Maine • Scarborough, Maine + 7 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 134
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Breast Cancer
- Interventions
- Abemaciclib, Letrozole
- Drug
- Lead sponsor
- Mridula George, MD
- Other
- Eligibility
- 60 Years and older · Female only
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2032
- U.S. locations
- 4
- States / cities
- Belleville, New Jersey • Livingston, New Jersey • New Brunswick, New Jersey + 1 more
- Conditions
- Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Hormone Receptor (HR)-Positive Breast Cancer
- Interventions
- Palbociclib, Everolimus, Exemestane
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Breast Cancer Metastatic
- Interventions
- Avasopasem
- Drug
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Breast Cancer
- Interventions
- Dato-DXd, Capecitabine, Gemcitabine, Eribulin, Vinorelbine
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 732 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 14
- States / cities
- Duarte, California • Los Angeles, California • Palo Alto, California + 10 more
- Conditions
- Early Breast Cancer
- Interventions
- LEE011 (ribociclib), letrozole
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 4
- States / cities
- Fayetteville, Arkansas • Los Angeles, California • Boston, Massachusetts + 1 more
- Conditions
- Metastatic Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Hormone Receptor Positive Breast Cancer
- Interventions
- Palbociclib, Bosutinib, Fulvestrant
- Drug
- Lead sponsor
- Georgetown University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Breast Cancer
- Interventions
- TTI-101, Palbociclib, Aromatase inhibitor (AI), fulvestrant, ribociclib
- Drug
- Lead sponsor
- Tvardi Therapeutics, Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 6
- States / cities
- Fort Lauderdale, Florida • St Louis, Missouri • Nashville, Tennessee + 2 more
- Conditions
- Advanced or Metastatic Breast Cancer
- Interventions
- PF-07220060 CDK4 inhibitor, Fulvestrant, Everolimus, Exemestane
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 333 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 9
- States / cities
- Irvine, California • Los Angeles, California • Newport Beach, California + 3 more
- Conditions
- Hormone Receptor Positive HER-2 Negative Breast Cancer
- Interventions
- Palbociclib + Letrozole or Fulvestrant
- Drug
- Lead sponsor
- Georgetown University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 6
- States / cities
- Washington D.C., District of Columbia • Chicago, Illinois • Baltimore, Maryland + 1 more
- Conditions
- Metastatic Breast Cancer, Locally Advanced Breast Cancer, Advanced Breast Cancer, BRCA2 Mutation, BRCA1 Mutation
- Interventions
- Palbociclib, Olaparib, Fulvestrant
- Drug
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, Metastatic Castration-resistant Prostate Cancer
- Interventions
- GVV858, Fulvestrant, Letrozole
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 205 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia • Nashville, Tennessee • San Antonio, Texas
- Conditions
- HER2-negative Breast Cancer, Hormone-receptor-positive Breast Cancer, Metastatic Breast Cancer, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, HER2 Negative Breast Carcinoma, Hormone Receptor Positive Breast Carcinoma, Metastatic Breast Carcinoma
- Interventions
- Biospecimen Collection
- Procedure
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Breast Cancer
- Interventions
- RGT-419B, RGT-419B in combination with hormonal therapy
- Drug
- Lead sponsor
- Regor Pharmaceuticals Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 8
- States / cities
- La Jolla, California • Los Angeles, California • Port Saint Lucie, Florida + 5 more
- Conditions
- Metastatic Breast Cancer
- Interventions
- Abemaciclib, Nonsteroidal Aromatase Inhibitor (NSAI)
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 70
- States / cities
- Daphne, Alabama • Tempe, Arizona • Fountain Valley, California + 60 more
- Conditions
- Breast Cancer
- Interventions
- Ribociclib, letrozole
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 6
- States / cities
- Sedona, Arizona • Long Beach, California • Charlotte, North Carolina + 3 more
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Malignant Neoplasm in the Brain, Metastatic Triple-Negative Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8
- Interventions
- Anti-HER2/HER3 Dendritic Cell Vaccine, Pembrolizumab
- Biological
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 3
- States / cities
- Tampa, Florida • Buffalo, New York • Charlottesville, Virginia
- Conditions
- Breast Cancer
- Interventions
- Not listed
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Breast Neoplasms
- Interventions
- Xentuzumab, Placebo, Everolimus, Exemestane
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 16
- States / cities
- Chandler, Arizona • Goodyear, Arizona • Beverly Hills, California + 13 more
- Conditions
- Ovarian Neoplasms, Peritoneal Neoplasms, Fallopian Tube Neoplasms, Triple Negative Breast Neoplasms, HER2 Negative Breast Neoplasms, Hormone Receptor Positive Breast Neoplasms, Endometrial Neoplasms, Carcinoma, Non-Small-Cell Lung, Cholangiocarcinoma, Gallbladder Carcinoma, Adenoid Cystic Carcinoma
- Interventions
- Felmetatug Vedotin, Pembrolizumab
- Drug
- Lead sponsor
- Seagen, a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 22
- States / cities
- Aurora, Colorado • Denver, Colorado • Celebration, Florida + 9 more
- Conditions
- Breast Cancer
- Interventions
- A CDK4/6 inhibitor different from the first that the participant had received, plus fulvestrant., Treatment of physician's choice
- Drug
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- Hormone Receptor Positive Breast Carcinoma, HER2-negative Breast Cancer
- Interventions
- OP-1250
- Drug
- Lead sponsor
- Olema Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 153 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 15
- States / cities
- Los Angeles, California • Aurora, Colorado • Deerfield Beach, Florida + 11 more
- Conditions
- Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer, Hormone-receptor-positive Breast Cancer, Hormone Receptor Positive Breast Carcinoma, Hormone Receptor Positive Malignant Neoplasm of Breast, HER2-negative Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer
- Interventions
- BGB-43395, Fulvestrant, Letrozole, Elacestrant, Anti-Diarrheal Agent
- Drug
- Lead sponsor
- BeOne Medicines
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 433 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 9
- States / cities
- Denver, Colorado • Lake Mary, Florida • Detroit, Michigan + 6 more
- Conditions
- Breast Neoplasms
- Interventions
- Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (PD-L1) antibody, Bevacizumab, Entinostat, Exemestane, Fulvestrant, Ipatasertib, Tamoxifen, Abemaciclib
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 144 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 14
- States / cities
- Birmingham, Alabama • San Francisco, California • Stanford, California + 11 more